Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 40

Results For "compliance"

403 News Found

Vivera Pharmaceuticals gets US patent for ZICOH
Biotech | August 23, 2021

Vivera Pharmaceuticals gets US patent for ZICOH

The software enables real-time communication between patients, caregivers, physicians, and pharmacists and each cartridge in the device has a unique, traceable serial number registered to the patient


Lupin posts net profit of Rs 542.46 cr. in Q1FY22
News | August 11, 2021

Lupin posts net profit of Rs 542.46 cr. in Q1FY22

The profits were bolstered by the Boehringer Ingelheim MEK program income


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


Covaxin receives approval from Hungary
Biotech | August 05, 2021

Covaxin receives approval from Hungary

More countries recognise Covaxin


Jubilant Pharmova’s Roorkee facility placed under import alert
News | July 16, 2021

Jubilant Pharmova’s Roorkee facility placed under import alert

The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.


Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
News | June 14, 2021

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination


Lupin receives warning letter from U.S. FDA
News | June 14, 2021

Lupin receives warning letter from U.S. FDA

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:


Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
News | April 05, 2021

Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19

PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents


Pharma 4.0: Pandemic pushed reluctant pharma companies to adopt advanced technologies
News | March 04, 2021

Pharma 4.0: Pandemic pushed reluctant pharma companies to adopt advanced technologies

Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.